Embargoed until 5 a.m. PT/8 a.m. ET, Monday, Nov. 13, 2017
ANAHEIM, California, Nov. 13 – The American Heart Association presented its 2017 Research Achievement Award to Thomas G. Brott, M.D., “for his pivotal role in the development of life-saving interventions that have revolutionized treatment of acute ischemic stroke, with enormous consequent benefits dramatically reducing stroke death and disability in the world’s population.”
Brott, of the Mayo Clinic in Jacksonville, Florida, received the award, a citation and $2,500 honorarium, during Sunday’s opening of the American Heart Association Scientific Sessions 2017, a premier global exchange of the latest advances in cardiovascular science for researchers and clinicians, which was held at the Anaheim Convention Center. AHA President John Warner, M.D., of the University of Texas Southwestern Medical Center at Dallas, made the presentation.
“Dr. Brott has been at the forefront of an international medical revolution in dealing with stroke, a worldwide health scourge that is a major cause of death and disability that annually afflicts nearly 17 million individuals, more than six million of whom die,” Warner said.
Prior to successful efforts by Brott and his fellow researchers, stroke was viewed as preventable but not treatable, the Association’s president said. “But that was before Dr. Brott’s team,in collaboration with the National Institute of Neurological Diseases and Stroke (NINDS) and a small group of investigators around the country, began to develop, test and implement what proved to be the first scientifically proven treatment for ischemic stroke, one that utilized a technique called endovascular reperfusion therapy, with a new drug, tissue plasminogen activator, or t-PA.”
The drug was shown to be highly effective in breaking up blood clots causing stroke, with the work by Brott and his team playing a leading role in proving its usefulness, Warner said. “This triggered a major reorganization of stroke care delivery systems and the development of new tools to more reliably recognize its severity,” he said. “Few medical scientists have contributed more to human well-being than Tom Brott.”
For more news at AHA Scientific Sessions 2017, follow us on Twitter @HeartNews #AHA17.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.
For Media Inquiries and AHA Spokesperson Perspective:
AHA News Media in Dallas: 214-706-1173
AHA News Media Office, Nov. 11-15, 2017 at the Anaheim Convention Center: 714-765-2004
For Public Inquiries: 800-AHA-USA1 (242-8721)